FREE SHIPPING over $40
OVER 10000 FIVE-STAR REVIEWS
5% OFF ALL SUBSCRIPTIONS
100% HAPPINESS GUARANTEE
Analyze Diet
0
Stem cell research & therapy2015; 6(1); 54; doi: 10.1186/s13287-015-0053-x

Equine allogeneic bone marrow-derived mesenchymal stromal cells elicit antibody responses in vivo.

Abstract: This study tested the hypothesis that Major Histocompatibility Complex (MHC) incompatible equine mesenchymal stromal cells (MSCs) would induce cytotoxic antibodies to donor MHC antigens in recipient horses after intradermal injection. No studies to date have explored recipient antibody responses to allogeneic donor MSC transplantation in the horse. This information is critical because the horse is a valuable species for assessing the safety and efficacy of MSC treatment prior to human clinical application. Methods: Six MHC heterozygote horses were identified as non-ELA-A2 haplotype by microsatellite typing and used as allogeneic MHC-mismatched MSC recipients. MHC homozygote horses of known ELA-A2 haplotype were used as MSC and peripheral blood leukocyte (PBL) donors. One MHC homozygote horse of the ELA-A2 haplotype was the recipient of ELA-A2 donor MSCs as an MHC-matched control. Donor MSCs, which were previously isolated and immunophenotyped, were thawed and culture expanded to achieve between 30x10(6) and 50x10(6) cells for intradermal injection into the recipient's neck. Recipient serum was collected and tested for the presence of anti-donor antibodies prior to MSC injection and every 7 days after MSC injection for the duration of the 8-week study using the standard two-stage lymphocyte microcytotoxicity dye-exclusion test. In addition to anti-ELA-A2 antibodies, recipient serum was examined for the presence of cross-reactive antibodies including anti-ELA-A3 and anti-RBC antibodies. Results: All MHC-mismatched recipient horses produced anti-ELA-A2 antibodies following injection of ELA-A2 MSCs and developed a wheal at the injection site that persisted for the duration of the experiment. Anti-ELA-A2 antibody responses were varied both in terms of strength and timing. Four recipient horses had high-titered anti-ELA-A2 antibody responses resulting in greater than 80% donor PBL death in the microcytotoxicity assays and one of these horses also developed antibodies that cross-reacted when tested on lymphocyte targets from a horse with an unrelated MHC type. Conclusions: Allogeneic MSCs are capable of eliciting antibody responses in vivo that can be strong and also cross-reactive with MHC types other than that of the donor. Such responses could limit the effectiveness of repeated allogeneic MSC use in a single horse, and could also result in untoward inflammatory responses in recipients.
Get Full Text
Publication Date: 2015-04-12 PubMed ID: 25889095PubMed Central: PMC4414005DOI: 10.1186/s13287-015-0053-xGoogle Scholar: Lookup
The Equine Research Bank provides access to a large database of publicly available scientific literature. Inclusion in the Research Bank does not imply endorsement of study methods or findings by Mad Barn.
LinkedInCopy
  • Journal Article
  • Research Support
  • N.I.H.
  • Extramural
  • Research Support
  • Non-U.S. Gov't

Summary

This research summary has been generated with artificial intelligence and may contain errors and omissions. Refer to the original study to confirm details provided. Submit correction.

This research studied the immune responses of recipient horses to the intradermal transplant of Major Histocompatibility Complex (MHC) incompatible equine mesenchymal stromal cells, finding that the transplants can elicit strong, potentially cross-reactive, antibody responses that could limit the effectiveness of repeated treatments.

Objectives and Methodologies

  • The primary objective of this study was to investigate the immunological reactions of horses when they receive a transplant of MHC incompatible equine mesenchymal stromal cells (MSCs). The researchers particularly wanted to determine any induced cytotoxic antibodies to the donor MHC antigens. The study sought to fill a research gap as no previous studies had examined potential antibody responses to allogeneic donor MSC transplantation in horses.
  • Six MHC heterozygote horses were selected as recipients for the transplanted cells, while MHC homozygote horses were used as cell and peripheral blood leukocyte donors. Donor cells had been previously isolated and immunophenotyped, and were subsequently culture-expanded to a quantity suitable for intradermal injection into the recipient horses’ neck.
  • Recipient horse serum was tested for the presence of anti-donor antibodies before the MSC injection and weekly thereafter for eight weeks. The researchers applied the two-stage lymphocyte microcytotoxicity dye-exclusion test method.

Results

  • All MHC-mismatched recipient horses displayed anti-ELA-A2 antibodies following injection with ELA-A2 MSCs and developed a persistent wheal at the injection site.
  • Anti-ELA-A2 antibody responses varied in strength and timing among the horses. Four of them had high-titered anti-ELA-A2 antibody responses that caused more than 80 percent donor PBL death in the microcytotoxicity assays.
  • One of these four horses showed remarkable cross-reactivity as it produced antibodies that reacted to lymphocyte targets from a horse with an unrelated MHC type.

Conclusion

  • Allogeneic MSCs have the potential to elicit in vivo antibody responses. They can be strong and cross-reactive with MHC types that are distinct from that of the donor.
  • This may limit the efficacy of repeated allogeneic MSC use in a single horse and it could also trigger unwanted inflammatory responses in the recipients.

Cite This Article

APA
Pezzanite LM, Fortier LA, Antczak DF, Cassano JM, Brosnahan MM, Miller D, Schnabel LV. (2015). Equine allogeneic bone marrow-derived mesenchymal stromal cells elicit antibody responses in vivo. Stem Cell Res Ther, 6(1), 54. https://doi.org/10.1186/s13287-015-0053-x

Publication

Stem cell research & therapy
ISSN: 1757-6512
NlmUniqueID: 101527581
Country: England
Language: English
Volume: 6
Issue: 1
Pages: 54
PII: 54

Researcher Affiliations

Pezzanite, Lynn M
  • Department of Clinical Sciences, College of Veterinary Medicine, Cornell University, Ithaca, NY, 14853, USA. lmp238@cornell.edu.
Fortier, Lisa A
  • Department of Clinical Sciences, College of Veterinary Medicine, Cornell University, Ithaca, NY, 14853, USA. laf4@cornell.edu.
Antczak, Douglas F
  • Baker Institute for Animal Health, Cornell University, Ithaca, NY, 14853, USA. dfa1@cornell.edu.
Cassano, Jennifer M
  • Department of Clinical Sciences, College of Veterinary Medicine, Cornell University, Ithaca, NY, 14853, USA. jmc292@cornell.edu.
Brosnahan, Margaret M
  • Baker Institute for Animal Health, Cornell University, Ithaca, NY, 14853, USA. mmb263@cornell.edu.
Miller, Donald
  • Baker Institute for Animal Health, Cornell University, Ithaca, NY, 14853, USA. dm96@cornell.edu.
Schnabel, Lauren V
  • Department of Clinical Sciences, College of Veterinary Medicine, North Carolina State University, Raleigh, NC, 27607, USA. lauren_schnabel@ncsu.edu.

MeSH Terms

  • Animals
  • Antibodies / immunology
  • Antibody Formation / immunology
  • Bone Marrow Cells / cytology
  • Bone Marrow Cells / immunology
  • Female
  • Horses
  • Inflammation / immunology
  • Major Histocompatibility Complex / immunology
  • Male
  • Mesenchymal Stem Cell Transplantation / methods
  • Mesenchymal Stem Cells / immunology
  • Transplantation, Homologous / methods

Grant Funding

  • K08 AR060875 / NIAMS NIH HHS
  • 1K08AR060875 / NIAMS NIH HHS

References

This article includes 44 references
  1. Majors AK, Boehm CA, Nitto H, Midura RJ, Muschler GF. Characterization of human bone marrow stromal cells with respect to osteoblastic differentiation.. J Orthop Res 1997 Jul;15(4):546-57.
    doi: 10.1002/jor.1100150410pubmed: 9379264google scholar: lookup
  2. Peister A, Mellad JA, Larson BL, Hall BM, Gibson LF, Prockop DJ. Adult stem cells from bone marrow (MSCs) isolated from different strains of inbred mice vary in surface epitopes, rates of proliferation, and differentiation potential.. Blood 2004 Mar 1;103(5):1662-8.
    doi: 10.1182/blood-2003-09-3070pubmed: 14592819google scholar: lookup
  3. Baxter MA, Wynn RF, Jowitt SN, Wraith JE, Fairbairn LJ, Bellantuono I. Study of telomere length reveals rapid aging of human marrow stromal cells following in vitro expansion.. Stem Cells 2004;22(5):675-82.
    doi: 10.1634/stemcells.22-5-675pubmed: 15342932google scholar: lookup
  4. Carter-Arnold JL, Neilsen NL, Amelse LL, Odoi A, Dhar MS. In vitro analysis of equine, bone marrow-derived mesenchymal stem cells demonstrates differences within age- and gender-matched horses.. Equine Vet J 2014 Sep;46(5):589-95.
    doi: 10.1111/evj.12142pubmed: 23855680google scholar: lookup
  5. Griffin MD, Ryan AE, Alagesan S, Lohan P, Treacy O, Ritter T. Anti-donor immune responses elicited by allogeneic mesenchymal stem cells: what have we learned so far?. Immunol Cell Biol 2013 Jan;91(1):40-51.
    doi: 10.1038/icb.2012.67pubmed: 23207278google scholar: lookup
  6. Stagg J, Galipeau J. Immune plasticity of bone marrow-derived mesenchymal stromal cells.. Handb Exp Pharmacol 2007;(180):45-66.
    doi: 10.1007/978-3-540-68976-8_3pubmed: 17554504google scholar: lookup
  7. Griffin MD, Ritter T, Mahon BP. Immunological aspects of allogeneic mesenchymal stem cell therapies.. Hum Gene Ther 2010 Dec;21(12):1641-55.
    doi: 10.1089/hum.2010.156pubmed: 20718666google scholar: lookup
  8. Stagg J. Immune regulation by mesenchymal stem cells: two sides to the coin.. Tissue Antigens 2007 Jan;69(1):1-9.
    doi: 10.1111/j.1399-0039.2006.00739.xpubmed: 17212702google scholar: lookup
  9. Tse WT, Pendleton JD, Beyer WM, Egalka MC, Guinan EC. Suppression of allogeneic T-cell proliferation by human marrow stromal cells: implications in transplantation.. Transplantation 2003 Feb 15;75(3):389-97.
    doi: 10.1097/01.TP.0000045055.63901.A9pubmed: 12589164google scholar: lookup
  10. Pittenger MF, Mackay AM, Beck SC, Jaiswal RK, Douglas R, Mosca JD, Moorman MA, Simonetti DW, Craig S, Marshak DR. Multilineage potential of adult human mesenchymal stem cells.. Science 1999 Apr 2;284(5411):143-7.
    doi: 10.1126/science.284.5411.143pubmed: 10102814google scholar: lookup
  11. Di Nicola M, Carlo-Stella C, Magni M, Milanesi M, Longoni PD, Matteucci P, Grisanti S, Gianni AM. Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli.. Blood 2002 May 15;99(10):3838-43.
    doi: 10.1182/blood.V99.10.3838pubmed: 11986244google scholar: lookup
  12. Le Blanc K, Mougiakakos D. Multipotent mesenchymal stromal cells and the innate immune system.. Nat Rev Immunol 2012 Apr 25;12(5):383-96.
    doi: 10.1038/nri3209pubmed: 22531326google scholar: lookup
  13. Le Blanc K, Tammik L, Sundberg B, Haynesworth SE, Ringdén O. Mesenchymal stem cells inhibit and stimulate mixed lymphocyte cultures and mitogenic responses independently of the major histocompatibility complex.. Scand J Immunol 2003 Jan;57(1):11-20.
    doi: 10.1046/j.1365-3083.2003.01176.xpubmed: 12542793google scholar: lookup
  14. Schnabel LV, Fortier LA, McIlwraith CW, Nobert KM. Therapeutic use of stem cells in horses: which type, how, and when?. Vet J 2013 Sep;197(3):570-7.
    doi: 10.1016/j.tvjl.2013.04.018pubmed: 23778257google scholar: lookup
  15. Schnabel LV, Lynch ME, van der Meulen MC, Yeager AE, Kornatowski MA, Nixon AJ. Mesenchymal stem cells and insulin-like growth factor-I gene-enhanced mesenchymal stem cells improve structural aspects of healing in equine flexor digitorum superficialis tendons.. J Orthop Res 2009 Oct;27(10):1392-8.
    doi: 10.1002/jor.20887pubmed: 19350658google scholar: lookup
  16. Fortier LA. Making progress in the what, when and where of regenerative medicine for our equine patients.. Equine Vet J 2012 Sep;44(5):511-2.
    doi: 10.1111/j.2042-3306.2012.00628.xpubmed: 22888773google scholar: lookup
  17. Fortier LA, Travis AJ. Stem cells in veterinary medicine.. Stem Cell Res Ther 2011 Feb 23;2(1):9.
    doi: 10.1186/scrt50pmc: PMC3092149pubmed: 21371354google scholar: lookup
  18. Frisbie DD, Smith RK. Clinical update on the use of mesenchymal stem cells in equine orthopaedics.. Equine Vet J 2010 Jan;42(1):86-9.
    doi: 10.2746/042516409X477263pubmed: 20121921google scholar: lookup
  19. Frisbie DD, Stewart MC. Cell-based therapies for equine joint disease.. Vet Clin North Am Equine Pract 2011 Aug;27(2):335-49.
    doi: 10.1016/j.cveq.2011.06.005pubmed: 21872762google scholar: lookup
  20. De Schauwer C, Van de Walle GR, Van Soom A, Meyer E. Mesenchymal stem cell therapy in horses: useful beyond orthopedic injuries?. Vet Q 2013 Dec;33(4):234-41.
    doi: 10.1080/01652176.2013.800250pubmed: 23697553google scholar: lookup
  21. Guest DJ, Ousey JC, Smith MR. Defining the expression of marker genes in equine mesenchymal stromal cells.. Stem Cells Cloning 2008;1:1-9.
    pmc: PMC3781685pubmed: 24198500doi: 10.2147/sccaa.s3824google scholar: lookup
  22. Carrade DD, Lame MW, Kent MS, Clark KC, Walker NJ, Borjesson DL. Comparative Analysis of the Immunomodulatory Properties of Equine Adult-Derived Mesenchymal Stem Cells().. Cell Med 2012;4(1):1-11.
    doi: 10.3727/215517912X647217pmc: PMC3495591pubmed: 23152950google scholar: lookup
  23. De Schauwer C, Meyer E, Van de Walle GR, Van Soom A. Markers of stemness in equine mesenchymal stem cells: a plea for uniformity.. Theriogenology 2011 May;75(8):1431-43.
    doi: 10.1016/j.theriogenology.2010.11.008pubmed: 21196039google scholar: lookup
  24. Schnabel LV, Pezzanite LM, Antczak DF, Felippe MJ, Fortier LA. Equine bone marrow-derived mesenchymal stromal cells are heterogeneous in MHC class II expression and capable of inciting an immune response in vitro.. Stem Cell Res Ther 2014 Jan 24;5(1):13.
    doi: 10.1186/scrt402pmc: PMC4055004pubmed: 24461709google scholar: lookup
  25. Poncelet AJ, Vercruysse J, Saliez A, Gianello P. Although pig allogeneic mesenchymal stem cells are not immunogenic in vitro, intracardiac injection elicits an immune response in vivo.. Transplantation 2007 Mar 27;83(6):783-90.
    doi: 10.1097/01.tp.0000258649.23081.a3pubmed: 17414713google scholar: lookup
  26. Isakova IA, Lanclos C, Bruhn J, Kuroda MJ, Baker KC, Krishnappa V, Phinney DG. Allo-reactivity of mesenchymal stem cells in rhesus macaques is dose and haplotype dependent and limits durable cell engraftment in vivo.. PLoS One 2014;9(1):e87238.
    doi: 10.1371/journal.pone.0087238pmc: PMC3906169pubmed: 24489878google scholar: lookup
  27. Badillo AT, Beggs KJ, Javazon EH, Tebbets JC, Flake AW. Murine bone marrow stromal progenitor cells elicit an in vivo cellular and humoral alloimmune response.. Biol Blood Marrow Transplant 2007 Apr;13(4):412-22.
    doi: 10.1016/j.bbmt.2006.12.447pmc: PMC1892590pubmed: 17382248google scholar: lookup
  28. Inoue S, Popp FC, Koehl GE, Piso P, Schlitt HJ, Geissler EK, Dahlke MH. Immunomodulatory effects of mesenchymal stem cells in a rat organ transplant model.. Transplantation 2006 Jun 15;81(11):1589-95.
    doi: 10.1097/01.tp.0000209919.90630.7bpubmed: 16770249google scholar: lookup
  29. Nauta AJ, Westerhuis G, Kruisselbrink AB, Lurvink EG, Willemze R, Fibbe WE. Donor-derived mesenchymal stem cells are immunogenic in an allogeneic host and stimulate donor graft rejection in a nonmyeloablative setting.. Blood 2006 Sep 15;108(6):2114-20.
    doi: 10.1182/blood-2005-11-011650pmc: PMC1895546pubmed: 16690970google scholar: lookup
  30. Lazary S, Antczak DF, Bailey E, Bell TK, Bernoco D, Byrns G, McClure JJ. Joint Report of the Fifth International Workshop on Lymphocyte Alloantigens of the Horse, Baton Rouge, Louisiana, 31 October-1 November 1987.. Anim Genet 1988;19(4):447-56.
    doi: 10.1111/j.1365-2052.1988.tb00836.xpubmed: 2466424google scholar: lookup
  31. Tallmadge RL, Lear TL, Antczak DF. Genomic characterization of MHC class I genes of the horse.. Immunogenetics 2005 Nov;57(10):763-74.
    doi: 10.1007/s00251-005-0034-9pubmed: 16220348google scholar: lookup
  32. Tseng CT, Miller D, Cassano J, Bailey E, Antczak DF. Identification of equine major histocompatibility complex haplotypes using polymorphic microsatellites.. Anim Genet 2010 Dec;41 Suppl 2(Suppl 2):150-3.
    doi: 10.1111/j.1365-2052.2010.02125.xpmc: PMC3289534pubmed: 21070289google scholar: lookup
  33. Tallmadge RL, Campbell JA, Miller DC, Antczak DF. Analysis of MHC class I genes across horse MHC haplotypes.. Immunogenetics 2010 Mar;62(3):159-72.
    doi: 10.1007/s00251-009-0420-9pmc: PMC2872545pubmed: 20099063google scholar: lookup
  34. Brinkmeyer-Langford CL, Cai JJ, Gill CA, Skow LC. Microsatellite variation in the equine MHC.. Anim Genet 2013 Jun;44(3):267-75.
    doi: 10.1111/age.12003pubmed: 23051181google scholar: lookup
  35. Bronzini I, Patruno M, Iacopetti I, Martinello T. Influence of temperature, time and different media on mesenchymal stromal cells shipped for clinical application.. Vet J 2012 Oct;194(1):121-3.
    doi: 10.1016/j.tvjl.2012.03.010pubmed: 22503718google scholar: lookup
  36. Antczak DF, Bright SM, Remick LH, Bauman BE. Lymphocyte alloantigens of the horse. I. Serologic and genetic studies.. Tissue Antigens 1982 Sep;20(3):172-87.
    doi: 10.1111/j.1399-0039.1982.tb00343.xpubmed: 6182639google scholar: lookup
  37. Adams AP, Antczak DF. Ectopic transplantation of equine invasive trophoblast.. Biol Reprod 2001 Mar;64(3):753-63.
    doi: 10.1095/biolreprod64.3.753pubmed: 11207188google scholar: lookup
  38. Sernee MF, Ploegh HL, Schust DJ. Why certain antibodies cross-react with HLA-A and HLA-G: epitope mapping of two common MHC class I reagents.. Mol Immunol 1998 Feb;35(3):177-88.
    doi: 10.1016/S0161-5890(98)00026-1pubmed: 9694518google scholar: lookup
  39. Adams AP, Oriol JG, Campbell RE, Oppenheim YC, Allen WR, Antczak DF. The effect of skin allografting on the equine endometrial cup reaction.. Theriogenology 2007 Jul 15;68(2):237-47.
    doi: 10.1016/j.theriogenology.2007.04.058pmc: PMC2259290pubmed: 17559923google scholar: lookup
  40. Horwitz EM, Gordon PL, Koo WK, Marx JC, Neel MD, McNall RY, Muul L, Hofmann T. Isolated allogeneic bone marrow-derived mesenchymal cells engraft and stimulate growth in children with osteogenesis imperfecta: Implications for cell therapy of bone.. Proc Natl Acad Sci U S A 2002 Jun 25;99(13):8932-7.
    doi: 10.1073/pnas.132252399pmc: PMC124401pubmed: 12084934google scholar: lookup
  41. Franchimont D. Overview of the actions of glucocorticoids on the immune response: a good model to characterize new pathways of immunosuppression for new treatment strategies.. Ann N Y Acad Sci 2004 Jun;1024:124-37.
    doi: 10.1196/annals.1321.009pubmed: 15265777google scholar: lookup
  42. Elenkov IJ, Webster EL, Torpy DJ, Chrousos GP. Stress, corticotropin-releasing hormone, glucocorticoids, and the immune/inflammatory response: acute and chronic effects.. Ann N Y Acad Sci 1999 Jun 22;876:1-11; discussion 11-3.
    doi: 10.1111/j.1749-6632.1999.tb07618.xpubmed: 10415589google scholar: lookup
  43. Elenkov IJ, Chrousos GP. Stress Hormones, Th1/Th2 patterns, Pro/Anti-inflammatory Cytokines and Susceptibility to Disease.. Trends Endocrinol Metab 1999 Nov;10(9):359-368.
    doi: 10.1016/S1043-2760(99)00188-5pubmed: 10511695google scholar: lookup
  44. Sharma RR, Pollock K, Hubel A, McKenna D. Mesenchymal stem or stromal cells: a review of clinical applications and manufacturing practices.. Transfusion 2014 May;54(5):1418-37.
    doi: 10.1111/trf.12421pmc: PMC6364749pubmed: 24898458google scholar: lookup

Citations

This article has been cited 62 times.
Subscribe to our newsletter
Join 99,970 horse owners like you who receive our email updates on horse health and nutrition.